Polpharma Biologics S.A. is required to prepare and publish information on the executed tax strategy in order to fulfill the obligation set forth in Article 27c paragraph 1 in connection with Article 27b paragraph 2 points 1 and 2 of the Corporate Income Tax Act of February 15, 1992. We invite you to read the document.
Information on the implemented tax strategy for 2023
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA
December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG,...
Polpharma Biologics and Libbs Farmacêutica sign licensing agreement for a biosimilar for autoimmune diseases
December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...
Polpharma Biologics confirms U.S. launch of Tyruko® (natalizumab), the first and only biosimilar for Multiple Sclerosis
November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development...
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab...